Joseph Tucker, Ph.D.

Chief Executive Officer, Director

Dr. Tucker is a seasoned executive who has built several publicly traded biotechnology companies. Dr. Tucker was a founder and Chief Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ: TRIL, TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and Chief Executive Officer of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.

Avani Kanubaddi

Chief Operating Officer

Former CEO of Welmedix, led brand sale to PE back healthcare company in 2019. Former Director at BMS/ConvaTec and Wyeth/Pfizer in Medical Device, Consumer Health segments.

LinkedIn

Robert G. Wilkins, M.D.

Chief Medical Officer

Former Medical Director at Abbott Laboratories. Business Development / Strategic planning roles with Baxter Healthcare & Battelle. Senior executive and consulting roles with multiple biomedical start-ups.

LinkedIn

Peter Facchini, Ph.D.

Chief Scientific Officer

Dr. Facchini has been a Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary for 25 years. Dr. Facchini held the Canada Research Chair in Plant Metabolic Processes Biotechnology and is currently a Parex Resources Innovation Fellow in the Faculty of Science. Dr. Facchini co-founded and was Chief Scientific Officer of Willow Biosciences Inc. and Epimeron Inc. Dr. Facchini has published over 160 scientific papers and co-invented over 30 patents. Dr. Facchini is an international leader in the biochemistry and biotechnology of natural product metabolism.

Learn More

Carter Ward

Chief Financial Officer

Prior to joining Enveric Biosciences, Mr. Ward served as Chief Financial Officer of Elite Pharmaceuticals, a specialty pharmaceutical company that develops and manufactures oral, controlled-release products. While at Elite, Mr. Ward successfully negotiated and executed capital raises, developed strategic initiatives, created financial models and led financial reporting efforts. Before joining Elite, Mr. Ward worked on the finance and supply chain team at Actavis USA, the U.S. subsidiary of European-based Actavis Group. At Actavis, Mr. Ward spearheaded the successful reengineering of the company's outbound supply chain. Mr. Ward has served in various capacities at other leading companies including Centennial Communications, Ceejay Healthcare and Petro Pharma.

LinkedIn

Jillian Hagel, Ph.D.

Chief Technology Officer

Dr. Hagel has over 19 years’ experience in plant biochemistry and natural products biosynthesis. Dr. Hagel held the position of Vice President, Applied Science and co-founder of Willow Biosciences Inc. (TSX: WLLW). Dr. Hagel was COO of Epimeron Inc. before the acquisition of Epimeron by Willow. Dr. Hagel has coauthored over 35 peer-reviewed publications and is the co-inventor on many patent applications. Dr. Hagel received her Ph.D. in natural products biochemistry in 2010 from the University of Calgary.

LinkedIn

David Johnson

Executive Chairman

Former CEO of Convatec, oversaw the $4.1B spin out of Convatec from Bristol Myers Squibb; former CEO of Alliqua Biomedical, a developer of wound care technologies.

LinkedIn

George Kegler

Director and Chair of the Audit Committee

Mr. Kegler was employed by Mallinckrodt Pharmaceuticals from January 2013 – June 2019, serving as the Executive Vice President and Chief Financial Officer, Interim from December 2018 – May 2019, where he had responsibility for the global finance function and was a member of the executive committee, Vice President Finance from November 2016 – November 2018, President Specialty Generics (Interim) and Vice President Finance from July 2016 – October 2016, and Vice President, Finance from January 2013 – June 2016. He has served in various consulting roles since June 2019. Mr. Kegler has 40 years of experience in financial planning and analysis, corporate finance, controllership and business development. Previously Mr. Kegler served as the vice president of commercial finance for various businesses within Mallinckrodt and was also interim president of the company’s specialty generics business. Prior to joining Mallinckrodt, he was the chief financial officer for Convatec a private equity-owned company that was purchased from Bristol-Myers Squibb. He worked in various finance roles within Bristol-Myers Squibb including commercial, International, technical operations, research & development as well as the assistant controller of internal controls. Mr. Kegler holds a bachelor’s degree in accounting from the University of Missouri, an MBA from Saint Louis University and completed the Certified Public Accountant exam in Missouri.

LinkedIn

Douglas Lind, M.D.

Director

Douglas Lind, M.D. has more than 30 years of experience working in a variety of life science-related professions, ranging from a former practicing physician, to a senior Wall Street equity research analyst at Morgan Stanley. Dr. Lind currently serves as a co-founder and Managing Partner at Biomark Capital, a Greenwich, Connecticut-based healthcare venture firm, where his investment focus includes cellular therapy, medical imaging, peripheral vascular disease, and oncology. Dr. Lind is a graduate of the University of Iowa College of Medicine. He was a practicing physician in Brookline, Massachusetts and was an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine.

LinkedIn

Sol Mayer

Director

Mr. Mayer has served as a member of the board of directors of DropCar, Inc (NASDAQ: DCAR) from 2018 through May of 2020. He has served as President and Chief Executive Officer of Mooney Aviation Company, a private company that manufactures four-place, single-engine and piston-powered aircraft, since 1999. He was a member of the board of directors of Microbot Medical, Inc (NASDAQ: MBOT) from 2014-2017. Prior to that time, he held the position of Chief Executive Officer of Overseas Trading, a department store wholesaler. Mr. Mayer currently serves as a director of Laniado Hospital, a voluntary, not-for-profit hospital in Netanya, Israel, as well as a director of several private companies. He previously served as a consultant to and director of each of Innovative Food Holdings, a provider of sourcing, preparation and delivery of specialty/fresh food for both professional chefs and consumers, and BlastGard International Inc., which manufactures and markets proprietary blast mitigation materials, in each case, from 2002 until 2016.

Marcus Schabacker, M.D., Ph.D.

Director

Dr. Schabacker became president and chief executive officer of the ECRI Institute, a nonprofit organization with 500 employees and an operating budget of $70 million focusing on advancing evidenced-based, effective healthcare globally, in January 2018. Prior to joining ECRI, Dr. Schabacker worked at Baxter Healthcare Corporation, serving as corporate vice president and chief scientific officer from July 2015–May 2017, chairman of the executive quality council from March 2014–May 2017, Chief Scientific Officer, Medical Products from July 2014–July 2015, and Vice President, R&D, Medical Products from March 2011–July 2014. During his clinical years, and his time as an industry thought leader, Dr. Schabacker was focused on patient safety and enhancing patient care. For over a decade Dr. Schabacker has served on numerous boards of small and midsize companies and organizations, providing management with guidance and expertise to strategically accelerate growth and to build successful and sustainable high performing management teams. Dr. Schabacker is a board-certified anesthesiologist and intensive care specialist with more than 35 years of healthcare experience in complex global environments, and more than 20 years of senior leadership responsibilities serving the medical device and pharmaceutical industries across the healthcare value chain.

LinkedIn

Brad Thompson, Ph.D.

Director

Dr. Thompson is an experienced biotechnology company founder and executive with 40 years experience in the public markets sector.

LinkedIn

St. George’s University of London (SGUL)

St. George’s University of London (SGUL) brings research capabilities and relevant domain experience in cancer and cannabinoids. Dr. Angus Daglesigh serves on Enveric Biosciences’ Scientific Advisory Board. Enveric Biosciences entered into a research collaboration agreement with SGUL, effective June 1, 2017, to carry out a project plan to develop treatment strategies related to CBD. Each party retained its background intellectual property rights, licensed the other party for purposes of the agreement, and Enveric Biosciences owns the results of the project and IP related to its materials and confidential information.

Visit Website

The Soroka University Medical Center

The Soroka University Medical Center brings clinical research capabilities and extensive patient access.Located in Be’er Sheva in the country’s most diverse and fastest-growing area, The Soroka University Medical Cancer Center is Israel’s leading medical center and one of its largest and most strategic institutions. The sole major medical center for the entire Negev region, Soroka serves over 1.2 million residents, including over 400,000 children, in an area that comprises 60% of Israel’s land. Home to Israel’s newest comprehensive Cancer Center, The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center represents peaceful coexistence in action, providing world-class healthcare for all.

Visit Website

University of Calgary

University of Calgary has entered a partnership that gives Enveric Biosciences access to the University’s facilities, research and innovation capabilities, a model that can be used in a number of different research areas.

Visit Website